SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Medivation, Inc.
(Nasdaq: MDVN) today announced that David Hung, M.D., president and chief
executive officer, will be a featured speaker on a panel entitled, 'A Focus on
Neurodegeneration -- Huntington's and Parkinson's Disease,' at the 7th Annual
BIO Investor Forum on Friday, October 31, at 9:45 a.m. Pacific Time at the
Palace Hotel in San Francisco.
Dr. Hung will also present at the Barclays Capital Small and Mid-cap
Healthcare Conference on Thursday, November 6, at 12:30 p.m. Eastern Time at
Barclays headquarters in New York and at the Lazard Capital Markets Fifth
Annual Healthcare Conference on Tuesday, November 18, at 10:55 a.m. Eastern
Time at the St. Regis in New York. He will provide an overview of Medivation
and its clinical development programs for Dimebon for Alzheimer's and
Huntington's diseases and MDV3100 for prostate cancer.
A live audio webcast of the presentation for both the Barclays Healthcare
Conference and the Lazard Capital Markets Healthcare Conference will be
available on the 'Events and Presentations' page of the 'Investor Relations'
section of the Company's website at http://www.medivation.com. A replay also
will be available for 30 days following the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel small molecule drugs to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients and
their caregivers. The Company's current clinical development program includes
a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and
a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant
(also known as hormone-refractory) prostate cancer. Medivation recently
announced that it plans to continue further development of Dimebon in patients
with mild-to-moderate Huntington's disease based on the positive results seen
in its Phase 2 trial. In September 2008, Medivation entered into a global
agreement with Pfizer Inc to develop and commercialize Dimebon for the
treatment of Alzheimer's and Huntington's diseases. For more information,
please visit us at http://www.medivation.com.
SOURCE Medivation, Inc.
